





Deadline	Tue 05 Mar 2024 12:00 (noon) CET Pre-proposals (IOCB deadline Tue 27 Feb 2024) Tue 25 Jun 2024 12:00 (noon) CEST Full-proposals (IOCB deadline Fri 21 Jun 2024)
Call name	The EU Joint Programme – Neurodegenerative Disease Research (JPND)
	Call 2024: "Mechanisms and measurement of disease progression in the early phase of neurodegenerative diseases"
www	JPND: https://neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/call-
	announcement-for-jpnd-2024-call-mechanisms-and-measurement-of-disease-progression-in-
	the-early-phase-of-neurodegenerative-diseases/
	MEYS: <u>https://www.msmt.cz/vyzkum-a-vyvoj-2/iniciativa-spolecneho-programovani-</u>
<b>F</b>	neurodegenerativni-5
Focused on	Fundamental, translational research
PI	Consortium of 3–6 (7 when from underrepresented countries: Hungary, Latvia, Poland, or Turkey) partners (represented by the leaders of individual research groups) represented by a coordinator.
Eligible	Research organisations, universities, hospitals, other health and social care settings,
organisation	commercial sector and SMEs - national restriction may apply.
	Participating countries: Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Luxembourg, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Turkey.
Target group	Multinational research groups collaboration: Consortium 3-6 partners from at least. 3
raiget group	countries, with participation of underrepresented countries up to 7 partners, max. 2 partners from the same country in 1 consortium
Expected outputs	Not specified (publications, etc.)
Call opens	04 Jan 2024
IOCB deadline	Tue 27 Feb 2024 Pre-proposals Fri 21 Jun 2024 Full-proposals
Final deadline	Tue 05 Mar 2024 12:00 (noon) CET Pre-proposals
	One joint proposal per consortium- submission website: https://ptoutline.eu/app/jpnd2024 Czech participants: MEYS: statutory declaration of each participant and planned budget (using the prescribed form) to be submitted preferably as digitally signed documents through the MEYS data box (ID <i>vidaawt</i> ). <b>Tue 25 Jun 2024 12:00 (noon) CEST Full-proposals -</b> same as pre-proposals.
Evaluation	Results of Pre-proposals assessment – end of May 2024
results	Results of Full-proposals assessment – Oct 2024
Signature of	
agreement	
Earliest date of	
implementation	Early 2025
Latest date of	
implementation	
Sustainability	none
Reporting	Brief annual scientific report in Jan of each year and final scientific progress report within 3
Reporting	months from project end.
	for Czech participants – MEYS, annual scientific and financial reports due 31 January of the following years);
Project duration (min-max)	up to 36 months
Allocation for the call	Total 18 M EUR, MEYS – 1 million EUR (anticipated 3-4 projects in CZ)
Project budget (min-max)	No restriction
Success rate	12 % (2019)
Eligible costs	Czech participant: §2 of the Act. No 130/2002 Coll. direct costs: personnel, consumables, equipment, travel, other costs
	indirect costs: overheads max 25 % (flat rate) of direct costs without subcontracting

	Only the research and knowledge-dissemination organizations are eligible for the MEYS support.
Reimbursement	100 % for fundamental/basic research activities, 50 % for applied research activities and 25 % for experimental development activities
Mode of funding	ex-ante
Language of application	English/Czech for MEYS
Provider	Consortium of 19 providers from 19 countries (for Czech participants – MEYS) Ministry of Education, Youth and Sports of the Czech Republic (MEYS/MŠMT), Prague, <u>www.msmt.cz</u> Mgr. Daniel Hanšpach, +420 234 811 360, <u>daniel.hanspach@msmt.cz</u> JPND Joint Call Secretariat: DLR-PT, Health Division (De); <u>www.jpnd.eu</u> Dr. Sabrina Voß or Dr Sara Breid; jpnd@dlr.de; (+49) 228-3821 2111
Call identifier	JPND 2024
Call info	The aim of the call is to establish a number of ambitious, innovative, multi-disciplinary and multi-national collaborative research projects that seek to improve the understanding of disease mechanisms and advancing measurability of disease progression at early and presymptomatic stages of neurodegenerative diseases.
Conditions / Restrictions	<ul> <li>Proposals submitted under this call may include, but are not limited to, the following types of research: <ul> <li>Unraveling the influence of molecular, physiological, psychological and social factors and pathways on disease progression as well as discovering new factors and pathways;</li> <li>Defining key regulatory steps affecting the disease onset and progression;</li> <li>Combining molecular, psychological, social and physiological markers in order to increase the robustness of the diagnosis;</li> <li>Harmonization of the use of novel technologies and clinical measures to increase</li> </ul> </li> </ul>
	<ul> <li>reliability and reproducibility of disease detection and monitoring;</li> <li>Identifying molecular, environmental, social and behavioral modulators of disease progression with the ultimate aim of determining risk, protective and resilience factors;</li> <li>Examining pathological processes related to neurodegeneration by using Artificial Intelligence and other cutting-edge technologies to understand the role of mechanistic pathways;</li> <li>Enhancing patient stratification by establishing measures and technologies to characterize clinical subgroups at pre-symptomatic stages, e.g. 'risk phenotypes' or 'at-risk' groups;</li> <li>Identifying compensatory mechanisms associated to early stages of neurodegenerative diseases; Systematically analyzing the influence of genetic,</li> </ul>
	<ul> <li>epigenetic and phenotypic variability underlying neurodegenerative diseases on disease progression;</li> <li>Proposals must also relate to any or several of the following neurodegenerative diseases:</li> <li>Alzheimer's disease and other dementias, Parkinson's disease and PD-related disorders, prion diseases, motor neuron diseases, Hungtington's disease, spinocerebellar ataxia and spinal muscular atrophy. JPND is committed to Patient and Public Involvement, and proposals are expected to engage patients, carers and the public. Training of young researchers and mobility is encouraged. To increase impact at the European level, it is encouraged to use European Research Infrastructure Networks such as BBMRI, EATRIS or ECRIN as valuable resources and platforms for knowledge exchange. Information can be found via the European Strategy Forum for Research Infrastructures in Europe - ESFRI. No annexes, CVs or Letter of Intent are allowed in the pre-proposals. Such information will be requested at the full-proposal stage.</li> <li>EU-13/Underrepresented countries: Hungary, Latvia, Poland, Turkey</li> </ul>
Proposal consists of	<ul> <li>Joint Pre-proposal application form: (max 6 pages)</li> <li>Synopsis: application details, the consortium and a scientific summary (keywords, disease/s addressed, abstract) (max. 1 page)</li> <li>Project description: aims, research questions, working hypothesis integrated into a description of the scientific background and of the present state of research, with special emphasis on transnational added value and specific expertise of the consortium members; some delineation of work plan, methodology (mostly expected in full proposal), references (max. 4 pages)</li> <li>Budget overview –costs requested for each partner, brief description (max. 1 page)</li> </ul>

	CZ: MEYS requested documentation:
	Eligible Costs Specification
	Statutory Declaration
Evaluation criteria	Relevance; Scientific quality; Transnational added value; International competitiveness (incl. diversity in gender, geographic and seniority); Deliverable outcomes; the criteria will be equally weighted. Full proposals will be additionally evaluated on: quality and accessibility of lay summary, dissemination plan, feasibility and quality of co-design, transcultural added value of PPI activities.
Research areas	All research areas and expertise relevant to the topic.
Call workshop	
IOCB contact	Please inform the IOCB Project Office (projectoffice@uochb.cas.cz) about your intention to apply. Do not hesitate to contact us for consulting, discussion or help. Veronika Palečková, <u>veronika.paleckova@uochb.cas.cz</u> , 420 220 183 266 Jitka Šilerová, jitka.silerova@uochb.cas.cz, +420 220 183 229 Blanka Collis, <u>blanka.collis@uochb.cas.cz</u> , +420 220 183 527 Lenka Štěrbová, <u>lenka.sterbova@uochb.cas.cz</u> , +420 220 183 179
Download	JPND-2024_Summary
documents	JPND-2024_Call
	JPND-2024_Procedures
	JPND-2024_Pre-proposal_Template
	JPND-2024_CZspecific
	JPND-2024_Czech guidelines
	JPND-2024_MEYS_Costs_Specification